The world’s leading pan-isotype therapeutic antibody company

We are a clinical-stage company, pioneering radically new antibody therapeutics for oncology.

We have unique and proprietary expertise in the discovery and development of IgE, IgA and IgG-based therapeutics with each isotype possessing differentiated immune effector function.

Evolved to treat parasitic infection, IgE has significant activity against various tumour types by activating myeloid cells and T cells thereby warming up the tumour micro-environment. IgA’s anti-cancer potential is mediated by the activation of neutrophils. The distinct activity profiles of each isotype allow us to select the most appropriate isotype for a given cancer.

Our lead clinical candidate, MOv18 IgE, targets folate receptor alpha (FRα). It has successfully completed a phase I trial in ovarian cancer and was found to be safe and well tolerated with early signs of clinical activity. A phase Ib trial of MOv18 IgE in platinum-resistant ovarian cancer (PROC) is underway.

Epsilogen has created a number of platforms based on its expertise with the IgE, IgA and IgG isotypes including bispecific IgE and IgEG antibodies.

Find out more about our business

Management Team

Tim Wilson, PhD.

Chief Executive Officer

Tim Wilson, PhD. Chief Executive Officer

Tim’s career in the life sciences has encompassed start-ups, venture capital, investment banking and equity research. He has held senior positions at a number of firms including NM Rothschild, Hambrecht and Quist, UBS, SG Cowen and Pacific Growth Equities. In 2013 he founded Longcross Advisers, a life science-focused corporate finance firm. He gained his PhD from the MRC’s Laboratory of Molecular Biology in Cambridge and a BSc (Hons) in biochemistry from Imperial College, London.

Kevin FitzGerald

Chief Scientific Officer

Kevin FitzGerald Chief Scientific Officer

Kevin began his career in the biotechnology industry at Cambridge Antibody Technology (now part of Medimmune, an AstraZeneca company) when CAT was still in its start-up phase. He went on to found and manage Isogenica Ltd and has since held CEO positions with PhosImmune Inc., Activiomics Ltd and F-star GmbH. Kevin studied for his PhD in the laboratory of Sir Gregory Winter at the MRC Laboratory of Molecular Biology, Cambridge and for his MBA at Aston Business School following receipt of a Sainsbury Management Fellowship from the Royal Academy of Engineering, London.

Cristina Oliva

Chief Medical Officer

Cristina Oliva Chief Medical Officer

Dr. Cristina Oliva is a board-certified medical oncologist with over 20 years of international experience in oncology drug development. Her career encompasses senior leadership roles within global pharmaceutical companies, biotechnology firms, and Clinical Research Organizations, where she has successfully advanced numerous oncology and onco-haematology compounds from early clinical stages through to regulatory approval and global market authorization. Cristina has held prominent positions including Vice President and Head of the Oncology Center of Excellence at IQVIA, Chief Medical Officer at Nordic Nanovector, and senior clinical development roles at Shionogi, Takeda Pharmaceuticals, GlaxoSmithKline, and Eli Lilly. Most recently, she served as Chief Medical Officer at BerGenBio, where she was responsible for leading all clinical development activities. She obtained her medical degree and oncology board certification from the University of Genoa in Italy, followed by a Doctorate in Public Health from Kingston University in London.

Nick Robbins-Cherry

Chief Financial Officer

Nick Robbins-Cherry Chief Financial Officer

Nick brings over 30 years of experience in fundraising, public markets and private equity, gained through financial and commercial roles in international pharmaceuticals and technology businesses. Nick was formerly CFO at Midatech Pharma PLC (now Biodexa Pharmaceuticals PLC), a listed pharmaceutical business with operations in the UK and Spain. He successfully steered Midatech through its IPO on AIM, a dual listing on NASDAQ and subsequent fundraises. Nick is a Chartered Accountant and holds a BSc in Pharmacology from Bath University and an MBA.

Elizabeth Hardaker

Chief Translational Science Officer

Elizabeth Hardaker Chief Translational Science Officer

Elizabeth has more than 15 years’ experience in the pharmaceutical industry. Most recently, Elizabeth was a Senior Director at AstraZeneca leading a team supporting preclinical research in Oncology. Prior to that Elizabeth worked at Evotec in the Inflammation and immunology group and Novartis in the Respiratory group. Throughout her career Elizabeth has been the biology lead on a number of projects from across the drug discovery process ranging from target validation to those in clinical trials. Elizabeth has a PhD from the National Heart and Lung Institute, Imperial College and a Masters in Biochemistry from Bath University.

Leanne Partington

VP of Product Development

Leanne Partington VP of Product Development

Leanne has over 20 years’ experience developing therapeutics from bench to clinic. She has worked as a scientist to develop vaccines at the Defence Science and Technology Laboratory (Dstl), GlaxoSmithKline on the development of small molecules and monoclonal antibodies and then the Cell and Gene Therapy Catapult with focus on the translation of cell and gene therapies. Leanne then moved into project management at University College London (UCL), working with academics and clinicians at UCL to secure translational research grants for the development of biologics, cell therapy and medical device modalities and then managing these grants with particular focus on funder liaison and sub-contractor management. She gained her EngD in Biochemical Engineering from University College London and is an APM PMQ qualified project manager.

Andrew Calam

VP of Clinical Operations

Andrew Calam VP of Clinical Operations

Andrew has over 25 years of experience in the life sciences industry, holding management and executive positions in both the CRO and biotechnology sector, supporting pharmaceutical development. Andrew started his career within the bioanalytical space before focusing on project management, leading multinational teams responsible for all aspects of clinical trial management in Phase I to Phase III trials. Prior to joining Epsilogen, Andrew worked as an Executive Director of Clinical Development at Syneos Health where he was responsible for the development, oversight, execution and management of several clinical programs for targeted cancer therapies. Andrew holds a BSc in Environment Chemistry from Leeds University.

Board of Directors

Tim Wilson, PhD.

Chief Executive Officer

Tim Wilson, PhD. Chief Executive Officer

Pete Finan

Non-Executive Chairman

Pete Finan Non-Executive Chairman

Pete joined Epidarex Capital as a Venture Partner in 2014. He has more than twenty years of experience in drug discovery within the pharmaceutical industry. Prior to joining Epidarex, he was Global Head of the Respiratory Disease Area and Site Head for the Novartis Institute of BioMedical Research in the United Kingdom. In this role, Peter had strategic and operational oversight for the respiratory portfolio from target discovery through to proof-of-concept trials in the clinic. He is a former Executive Director of the Novartis Developmental and Molecular Pathways Platform based in Cambridge, Massachusetts. Peter holds a BSc and Ph.D. in Biochemistry and Molecular Biology from the University of Leeds.

Marianne Uteng

Board Member

Marianne Uteng Board Member

Marianne Uteng PhD is a Managing Director at NVF in Basel, Switzerland. Prior to that, she worked in Novartis Global Drug Development, and in the Pre-Clinical Safety Department where she led teams delivering health authority-required and non-routine safety assessments for early and late-stage programs. She also supported the Novartis BD&L Search & Evaluation, and spearheaded collaborations with biotech companies and academia. Marianne received her MSc in Biochemistry from the University of Oslo and her PhD in Molecular Biology, Cell Biology & Biophysics in a joint program between EMBL and the University of Oslo.

Marianne Bjørdal

Board Member

Marianne Bjørdal Board Member

Marianne is a Partner at 3B Future Health Ventures, advisor to a venture capital fund investing in early-stage companies developing novel technologies and new treatments in oncology and rare diseases. Prior to joining 3B Future Health Ventures, she worked as a researcher for the French National Centre for Scientific Research (CNRS) studying cellular and molecular mechanisms in the brain integrating nutritional cues and regulating neuroendocrine signaling to control organismal growth and metabolism. She is a former Marie Curie Early-Stage Researcher and was awarded the AXA Prize from the French Academy of Science in 2014. Marianne received an M.Sc. in Molecular Biology from the University of Bergen in Norway, a Ph.D. in Molecular and Cellular Biology from the University of Nice in France and an MBA from the IAE Nice Graduate School of Management, France.

Alek Safarian

Board Member

Alek Safarian Board Member

Alek Safarian is the CEO of venture investment firm, ALSA Holdings Ltd. Alek has a diverse background in drug development spanning some 30 years. Trained as a pharmacist, he worked in regulatory affairs and clinical research roles for European and US based multinational pharmaceutical companies in Australia, with responsibility across the Asia-Pacific. He subsequently founded Novotech, a Sydney based contract research organisation working with hundreds of clinical stage biotech companies over a 21 year period. Alek holds a B. Pharm and MBA from the University of Sydney.

Emma Johnson

Board Member

Emma Johnson Board Member

Emma is a Senior Investment Manager in the British Patient Capital Direct Investments team, where she focuses on opportunities in the life sciences. Emma joined the BPC team in September 2021 at the launch of Future Fund: Breakthrough and has led investments into companies spanning novel therapeutic modalities and technologies driving efficiencies in the life sciences sector. Previously, Emma spent three years investing in a broad array of life sciences companies for the Greater Manchester and Cheshire Life Sciences Fund managed by Catapult Ventures. Emma also joined Fund Her North as a founding member with the goal of increasing access to finance for female entrepreneurs in the North of England and has a background in Neuroscience.

Sonia Gulati

Board Member

Sonia Gulati Board Member

Sonia Gulati, PhD is a Principal at the Global BioAccess Fund. She has a broad background in life sciences venture capital, biotechnology strategy consulting and basic science research. Prior to joining the Fund, Sonia served as an Executive in Residence (EIR) at Kairos Ventures, where she focused on venture creation. As an EIR,
she was responsible for both driving the investment process and acting as interim CEO for her newly formed portfolio companies.

Before joining Kairos Ventures, Sonia was Assistant Director at New York Ventures, where she managed the life sciences portfolio. Prior to her move to investing, Sonia worked at a boutique healthcare consultancy where she helped shape product launch and life cycle management strategies for biopharma.

Sonia completed her post-doctoral studies and received her PhD from the Vagelos College of Physicians and Surgeons, Columbia University. She has a B.A. from Barnard College, Columbia University.

Advisers

Robert Coleman

Clinical Advisor

Robert Coleman Clinical Advisor

Dr Robert Coleman is Chief Scientific Officer at The US Oncology Network, one of the largest networks of integrated, community-based oncology practices in the US. Dr Coleman leads one of the largest research programs in the country drawing from a network of more than 1,000 experienced investigators and dedicated clinical staff who specialise in oncology clinical trials. Dr Coleman’s work has been published extensively in more than 600 peer-reviewed articles, book chapters and textbooks, including over 300 peer-reviewed articles. He is the current President of the International Gynaecologic Cancer Society and has served as President of the Society of Gynaecologic Oncology. He serves on the Board of Directors for GOG-Foundation as is Co-Director for GOG-Partners.

Susana Banerjee

Clinical Advisor

Susana Banerjee Clinical Advisor

Dr Susana Banerjee, is a Consultant Medical Oncologist and Research Lead for the Gynaecology Unit at The Royal Marsden NHS Foundation Trust and Reader in Women’s Cancers at the Institute of Cancer Research, London, UK. Dr Banerjee has been involved in international specialist groups including the European Organisation for Research and Treatment of Cancer (EORTC) Executive Steering Committee for Gynaecological Cancers, and European Society of Medical Oncology (ESMO) Scientific Committee. She has led national and international trials, authored over 120 peer-reviewed articles and currently serves on the European Society of Medical Oncology (ESMO) Executive Board. Dr Banerjee graduated from Cambridge University and gained a PhD from the Institute of Cancer Research.

Thomas Herzog

Clinical Advisor

Thomas Herzog Clinical Advisor

Dr Thomas Herzog is the Deputy Director of the University of Cincinnati Cancer Center and an endowed professor of Obstetrics and Gynaecology at the UC College of Medicine. Dr Herzog is a National Institutes of Health and American Cancer Society funded researcher with over 300 published manuscripts. Dr Herzog has served on the board of directors or leadership council of the Society of Gynaecologic Oncology, the Foundation for Women’s Cancer, American College of Surgeons Board of Governors, American Board of Obstetrics and Gynaecology, GOG Foundation and the International Gynaecologic Cancer Society.